leadf
logo-loader
viewAnteris Technologies Ltd

Admedus Ltd wins the peer voted ‘Manufacturer of the Year’ award

Admedus was also awarded ‘Most Innovative Manufacturing Company’ for its work in the research, manufacture and export of its lead regenerative tissue product CardioCel®.

au_admedus_lee_presenting_at_award_ceremony_358.jpg

Admedus Ltd (ASX:AHZ) was awarded ‘Manufacturer of the Year’ at the 2016 Manufacturers’ Monthly Endeavour Awards dinner held in Sydney on Thursday, 12 May.

Admedus was chosen from over 40 other finalists to take out the major award on the night.

Admedus was also awarded ‘Most Innovative Manufacturing Company’ for its work in the research, manufacture and export of its lead regenerative tissue product CardioCel®, which is undertaken at the company’s state-of-the-art bio-manufacturing facility in Malaga, Western Australia.

Lee Rodne, managing director, commented: “We are extremely pleased to have been awarded Manufacturer of the Year and grateful to have been chosen from such a strong field.

"It is an honour to have our innovation and quality in manufacturing recognised by the industry.”


CardioCel

Admedus’ state-of-the-art bio-manufacturing facility was officially opened in August 2014 in order to support global demand for the company’s lead regenerative tissue product CardioCel.

CardioCel is developed using a high-tech engineering process called ADAPT®, whereby scientists treat a piece of animal pericardium (the heart covering membrane) to remove all RNA, DNA and remnants of cells to produce an off-the-shelf, ready to use collagen bio-scaffold that functions like human tissue.

The Admedus bio-manufacturing facility is equipped with in-house research and development labs, which allows Admedus scientists to work closely with the manufacturing team to refine CardioCel, as well as develop and distribute a portfolio of regenerative tissue products for soft tissue repair in the future.

Rodne added: “Admedus continues to invest in our Malaga bio-manufacturing facility to ensure expanded production based on global demand for CardioCel, as well as refine and develop current processes to accommodate for new products and product improvements.”

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Quick facts: Anteris Technologies Ltd

Price: 3.75 AUD

ASX:AVR
Market: ASX
Market Cap: $22.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read